223 related articles for article (PubMed ID: 29782359)
1. BRCA1 Mutations Associated With Increased Risk of Brain Metastases in Breast Cancer: A 1: 2 Matched-pair Analysis.
Zavitsanos PJ; Wazer DE; Hepel JT; Wang Y; Singh K; Leonard KL
Am J Clin Oncol; 2018 Dec; 41(12):1252-1256. PubMed ID: 29782359
[TBL] [Abstract][Full Text] [Related]
2. Central nervous system metastases in breast cancer patients with germline BRCA pathogenic variants compared to non-carriers: a matched-pair analysis.
Ben-Zion Berliner M; Yust-Katz S; Lavie I; Goldberg Y; Kedar I; Yerushalmi R
BMC Cancer; 2024 Feb; 24(1):219. PubMed ID: 38365640
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer.
Sønderstrup IMH; Jensen MB; Ejlertsen B; Eriksen JO; Gerdes AM; Kruse TA; Larsen MJ; Thomassen M; Laenkholm AV
Acta Oncol; 2019 Mar; 58(3):363-370. PubMed ID: 30614364
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Proteomic Profiling-derived Immunohistochemistry-based Prediction Models for BRCA1 and BRCA2 Germline Mutation-related Breast Carcinomas.
Vos S; Elias SG; van der Groep P; Smolders YH; van Gils CH; van Diest PJ
Am J Surg Pathol; 2018 Sep; 42(9):1262-1272. PubMed ID: 29979200
[TBL] [Abstract][Full Text] [Related]
5. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
6. Prognosis of BRCA1/2-negative breast cancer patients with HBOC risk factors compared with sporadic breast cancer patients without HBOC risk factors.
Ryu JM; Nam SJ; Kim SW; Lee JE; Chae BJ; Lee SK; Yu J
Jpn J Clin Oncol; 2020 Feb; 50(2):104-113. PubMed ID: 31926487
[TBL] [Abstract][Full Text] [Related]
7. Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
Song Y; Barry WT; Seah DS; Tung NM; Garber JE; Lin NU
Cancer; 2020 Jan; 126(2):271-280. PubMed ID: 31581314
[TBL] [Abstract][Full Text] [Related]
8. Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations.
Akkoc Mustafayev FN; Shukla MA; Lanier A; Milton DR; Gutierrez AM; Gruschkus SK; Lewis JE; Murthy RK; Arun BK
Cancer; 2024 May; 130(9):1600-1608. PubMed ID: 38100492
[TBL] [Abstract][Full Text] [Related]
9. Comparison of nodal metastasis between BRCA mutation carriers and non-BRCA mutation carriers with breast cancer.
Noori SF; Gangi A; Nelson ME; Choi M; Mirzadehgan P; Bonk AK; Mirocha J; Amersi F; Giuliano AE
Ann Surg Oncol; 2014 Oct; 21(10):3324-9. PubMed ID: 25047471
[TBL] [Abstract][Full Text] [Related]
10. The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: Screening of 2,991 patients and 1,043 controls by next-generation sequencing.
Lang GT; Shi JX; Hu X; Zhang CH; Shan L; Song CG; Zhuang ZG; Cao AY; Ling H; Yu KD; Li S; Sun MH; Zhou XY; Huang W; Shao ZM
Int J Cancer; 2017 Jul; 141(1):129-142. PubMed ID: 28294317
[TBL] [Abstract][Full Text] [Related]
11. Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer.
Golan T; Sella T; O'Reilly EM; Katz MH; Epelbaum R; Kelsen DP; Borgida A; Maynard H; Kindler H; Friedmen E; Javle M; Gallinger S
Br J Cancer; 2017 Mar; 116(6):697-702. PubMed ID: 28183138
[TBL] [Abstract][Full Text] [Related]
12. Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status.
Stasenko M; Cybulska P; Feit N; Makker V; Konner J; O'Cearbhaill RE; Alektiar KM; Beal K; Gardner GJ; Long Roche KC; Sonoda Y; Chi DS; Zivanovic O; Leitao MM; Cadoo KA; Tew WP
Gynecol Oncol; 2019 Jul; 154(1):144-149. PubMed ID: 31113680
[TBL] [Abstract][Full Text] [Related]
13. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
[TBL] [Abstract][Full Text] [Related]
14. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study.
Golan T; Raitses-Gurevich M; Kelley RK; Bocobo AG; Borgida A; Shroff RT; Holter S; Gallinger S; Ahn DH; Aderka D; Apurva J; Bekaii-Saab T; Friedman E; Javle M
Oncologist; 2017 Jul; 22(7):804-810. PubMed ID: 28487467
[TBL] [Abstract][Full Text] [Related]
15. DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.
Aleskandarany M; Caracappa D; Nolan CC; Macmillan RD; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2015 Feb; 150(1):81-90. PubMed ID: 25690937
[TBL] [Abstract][Full Text] [Related]
16. Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings.
Houts AC; Olufade T; Shenolikar R; Walker MS; Schwartzberg LS
Cancer Treat Res Commun; 2019; 19():100121. PubMed ID: 30785027
[TBL] [Abstract][Full Text] [Related]
17. Biologic behavior of resected BRCA-mutated pancreatic cancer: Comparison with sporadic pancreatic cancer and other BRCA-related cancers.
Kim SH; Hwang HK; Lee WJ; Kang CM
Pancreatology; 2021 Apr; 21(3):544-549. PubMed ID: 33612442
[TBL] [Abstract][Full Text] [Related]
18. Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis.
Gargiulo P; Pensabene M; Milano M; Arpino G; Giuliano M; Forestieri V; Condello C; Lauria R; De Placido S
BMC Cancer; 2016 Jul; 16():375. PubMed ID: 27377827
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer immunohistochemical features in young women with BRCA 1/2 mutations.
Zakhartseva LM; Gorovenko NG; Podolskaya SV; Anikusko NF; Lobanova OE; Pekur KA; Kropelnytskyi VA; Shurygina OV
Exp Oncol; 2009 Sep; 31(3):174-8. PubMed ID: 19877382
[TBL] [Abstract][Full Text] [Related]
20. BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapy.
Takada M; Nagai S; Haruta M; Sugino RP; Tozuka K; Takei H; Ohkubo F; Inoue K; Kurosumi M; Miyazaki M; Sato-Otsubo A; Sato Y; Ogawa S; Kaneko Y
Genes Chromosomes Cancer; 2017 May; 56(5):405-420. PubMed ID: 28124401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]